Anemia of hemodialysis patients evaluation of the effect of BK-F polymethylmethacrylate membrane

Contributions to Nephrology

Volumn 125, Issue , 1999, Pages 173-181

  Locatelli, Francesco ^a   Andrulli, Simeone ^a   Vecchio, Lucia Del ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; BIOMATERIAL; ERYTHROPOIETIN; POLY(METHYL METHACRYLATE); RECOMBINANT PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; ARTIFICIAL MEMBRANE; BLOOD; CARDIOVASCULAR DISEASE; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ERYTHROID PRECURSOR CELL; FEMALE; HUMAN; HYPOXEMIA; INFORMED CONSENT; INSTRUMENTATION; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PERMEABILITY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; UREMIA;

ADULT; AGED; ANEMIA; ANOXEMIA; BIOCOMPATIBLE MATERIALS; BIOLOGICAL FACTORS; CARDIOVASCULAR DISEASES; ERYTHROID PROGENITOR CELLS; ERYTHROPOIETIN; FEMALE; HUMANS; INFORMED CONSENT; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; PERMEABILITY; POLYMETHYL METHACRYLATE; RECOMBINANT PROTEINS; RENAL DIALYSIS; UREMIA;

EID: 0032607850     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (30)

1. Locatelli F, Marcelli D, Conte F: Dialysis patient outcomes in Europe vs. the USA. Why do Europeans live longer? Nephrol Dial Transplant 1997;12:1816-1819.
2. US Renal Data System: USRDS 1997 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md. Causes of death. Am J Kidney Dis 1997;30(suppl 1):107-117.
3. Marcelli D, Stannard D, Conte F, Held PJ, Locatelli F, Port FK: ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int 1996; 50:1013-1018.
4. Raine AEG, MacMahon SH, Selwood NH, Wing AJ, Brunner FP: Mortality from myocardial infarction in patients on renal replacement therapy in the UK. Nephrol Dial Transplant 1991;6: 902-910.
5. Parfrey PS, Harnett JD, Foley RN: Heart failure and ischaemic heart disease in chronic uraemia. Curr Opin Nephrol Hypertens 1995;4:105-110.
6. Amann K, Neusu BR, Ritz E, Irzyniec T, Wiest G, Mall G: Changes of vascular architecture independent of blood pressure in experimental uremia. Am J Hypertens 1995;8:409-417.
7. Walker R: General management of end-stage renal disease. BMJ 1997;315:1429-1432.
8. Silberberg DS, Barre P, Prichard S, Sniderman AD: Left ventricular hypertrophy: An independent determinant of survival in end-stage renal failure. Kidney Int 1989;36:286-290.
9. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996;11:1277-1285.
10. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28: 53-61.
11. Washio M, Okuda S, Mizoue T, Kiyama S, Ando T, Sanai T, Hirakata H, Nanishi F, Kiyohara C, Ogimoto I, Yoshimura T, Fujishima M: Risk factors for left ventricular hypertrophy in chronic hemodialysis patients. Clin Nephrol 1997;47:362-366.
12. Cannella G, Paoletti E, Delfino R: Regression of left ventricular hypertrophy in hypertensive dialysed uremic patients on long-term antihypertensive therapy. Kidney Int 993;44:881-886.
13. Cannella G, La Canna G, Sandrini M: Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anemic dialysed uremic patients. Nephrol Dial Transplant 1991; 6:31-37.
14. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients requiring haemodialysis. BMJ 1990; 300:573-578.
15. Fellner SK, Lang RM, Nuemann A, Korcal C, Boron KM: Cardiovascular consequences of correction of the anaemia of renal failure with erythropoietin. Kidney Int 1993;44:1309-1315.
16. Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J: Regression of left ventricular hypertrophy after partial correction of anaemia with erythropoietin in patients on haemodialysis: A prospective study. Clin Nephrol 1991;35:280-287.
17. Locatelli F, Conte F, Marcelli D: The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 1998;13:1642-1644.
18. Anemia Work Group for National Kidney Foundation - Dialysis Outcomes Quality Initiative (NKF-DOQI): Clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997;30(suppl 3): 192-240.
19. Eschbach JW: The anemia of chronic renal failure: Pathophysiology and the effect of recombinant erythropoietin. Kidney Int 1989;35:134-148.
20. Locatelli F, Manzoni C: Biocompatibility in haemodialysis: Fact and fiction. Curr Opin Nephrol Hypertens 1997;6:528-532.
21. Ifudu O, Feldman J, Friedman EA: The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996;334:420-425.
22. Radtke HW, Frei U, Erbes PM, Schoeppe W, Koch KM: Improving anemia by hemodialysis. Effect on serum erythropoietin. Kidney Int 1980;17:382-387.
23. Radtke HW, Rege AB, Lamarche B, Bartos D, Bartos F, Cambell RA, Fisher JW: Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J Clin Invest 1981;67:1623-1629.
24. Massry SG: Is parathyroid hormone an uremic toxin? Nephron 1977;19:125-130.
25. Caro J, Erslev AJ: Uremic inhibitors of erythropoiesis. Semin Nephrol 1985;5:128-132.
26. Eschbach JW, Hley NR, Egrie JC, Adamson JW: A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney Int 1992;42:407-416.
27. Erselev AJ, Besarab A: The rate and control of baseline red cell production in hematologically stable patients with uremia. J Lab Clin Med 1995;126:283-286.
28. McGonigle RJS, Wallin JD, Shadduck RK, Fisher JW: Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 1984;25:437-444.
29. Niwa T, Yazawa T, Kodama T: Efficient removal of albumin bound furancarboxylic acid, an inhibitor of erythropoiesis by continuous ambulatory peritoneal dialysis. Nephron 1990;56:241-245.
30. Kobayashi H, Ono T, Yamamoto N, Hashimoto T, Fukuda T, Yamada S, Kai C, Kataoka H, Kobayashi T, Sonoda T: Removal of high molecular weight substances with large pore size membrane (BK-F). Kidney Dial 1993;34(suppl):154-157.